Document is current
Any future updates will be listed below
-
Authors
Dresse, Menayit Tamrat
Ferreira, Pamela C. L.
Prasadan, Akshay
Diaz, Jihui L.
Zeng, Xuemei
Bellaver, Bruna
Povala, Guilherme
Villemagne, Victor L.
Kamboh, M. Ilyas
Cohen, Ann D.
Pascoal, Tharick A.
Ganguli, Mary
Snitz, Beth E.
Shaaban, C. Elizabeth
Karikari, Thomas K.
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 29 June 2025
First Online: 25 July 2025
Declarations
:
: The MYHAT-NI study was performed under written informed consent and approved by the University of Pittsburgh Institutional Review Board (STUDY19020264). This study was performed in accordance with the Declaration of Helsinki.
: All participants gave written informed consent, and all study procedures were approved by the Institutional Review Board of the University of Pittsburgh.
: XZ is a listed inventor on the University of Pittsburgh provisional patent #63/672,952. CES is the Co-Chair of the ISTAART Sex and Gender Interest Group, Diversity and Disparities Professional Interest Area and a member of the ISTAART Advisory Council. TKK has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, has served on advisory boards for Siemens Healthineers and Neurogen Biomarking LLC, and has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, outside the submitted work. TKK has received royalties from Bioventix for the transfer of specific antibodies and assays to third party organizations. He has received honoraria for speaker/grant review engagements from the NIH, UPENN, UW‐Madison, Advent Health Translational Research Institute, Brain Health conference, Barcelona‐Pittsburgh conference, the International Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec Center for Drug Discovery, Canada, all outside of the submitted work. TKK is an inventor on several patents and provisional patents regarding biofluid biomarker methods, targets and reagents/compositions, that may generate income for the institution and/or self should they be licensed and/or transferred to another organization. These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; US63/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer’s Disease Patients; US63/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer 's Disease; US63/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric tau and soluble tau aggregates.
